Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) to Equal Weight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Jefferies Downgrades Ironwood Pharmaceuticals (IRWD) to Hold
April 15, 2025 2:54 AM EDTJefferies analyst Amy Li downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Buy to Hold with a price target of $0.70 (from $8.00).
The analyst comments: "Stepping back, we believed that glepa's CRL wouldn't read across to IRWD given apra's more robust clinical package at the to-be-marketed dose &... More
Citizens JMP Downgrades Ironwood Pharmaceuticals (IRWD) to Market Perform
April 14, 2025 11:35 AM EDTCitizens JMP analyst Jason Butler downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.
Shares of Ironwood Pharmaceuticals closed at $0.95 yesterday.
... MoreIronwood Pharmaceuticals (IRWD) PT Lowered to $1 at Leerink Partners
April 14, 2025 10:29 AM EDTLeerink Partners analyst Faisal A. Khurshid lowered the price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) to $1.00 (from $3.00) while maintaining a Market Perform rating.
The analyst comments "IRWD announced they will need to run an additional confirmatory Ph 3 trial for apraglutide in short... More
Ironwood Pharma (IRWD) Provides Clinical and Regulatory Update on Apraglutide
April 14, 2025 7:02 AM EDTIronwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that, based on a recent discussion with the U.S. Food and Drug Administration (FDA), a confirmatory Phase 3 trial is needed to seek approval of apraglutide... More
